Open Access

REVIEW

The role of FZR1 in tumorigenesis: Focus on cell-cycle control

HUI LI¹, CHENGFANG ZHOU², MEI KUANG², YUN LIU^1,*, JIEPING CHEN^1,2,*

1 Guizhou Provincial College-Based Key Lab for Tumor Prevention and Treatment with Distinctive Medicines, Zunyi Medical University, Zunyi, 563000, China
2 Department of Hematology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China

* Corresponding Authors: YUN LIU. Email: ; JIEPING CHEN. Email:

BIOCELL 2023, 47(10), 2177-2186. https://doi.org/10.32604/biocell.2023.029373

Received 15 February 2023; Accepted 21 June 2023; Issue published 08 November 2023

Abstract

Fizzy-related protein homolog 1 (FZR1) mainly functions as a specific activator of the anaphase-promoting complex/cyclosome (APC/C) in the cell cycle and controls the G0 and G1 phases of the cell cycle. We highlight recent work that has studied the role of FZR1 in tumorigenesis, growth, differentiation, and genome stability through cell-cycle control. We summarize the current state of knowledge regarding FZR1 structure, function, and the distinct ways of APC/C dysregulation in solid tumors and hematologic malignancies. We also discuss novel approaches for targeting the FZR1 as a cancer therapy and research area for future work.

---

Keywords

---